Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication February 8, 2021
- Revision received April 13, 2021
- Published online January 3, 2022.
Article Versions
- previous version (April 30, 2021 - 12:36).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2022 by the Society of Nuclear Medicine and Molecular Imaging.
Author Information
- Lukas Kessler1,2,
- Justin Ferdinandus1,2,
- Nader Hirmas1,2,
- Sebastian Bauer2,3,
- Uta Dirksen2,4,
- Fadi Zarrad1,2,
- Michael Nader1,2,
- Michal Chodyla2,5,
- Aleksandar Milosevic2,5,
- Lale Umutlu2,5,
- Martin Schuler2,3,
- Lars Erik Podleska2,6,
- Hans-Ulrich Schildhaus2,7,
- Wolfgang P. Fendler1,2 and
- Rainer Hamacher2,3
- 1Department of Nuclear Medicine, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;
- 2German Cancer Consortium, Partner Site University Hospital Essen, and German Cancer Research Center, Essen, Germany;
- 3Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany;
- 4Department of Pediatrics III, West German Cancer Center, University Hospital Essen, Essen, Germany;
- 5Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany;
- 6Department of Tumor Orthopedics and Sarcoma Surgery, University Hospital Essen, Essen, Germany; and
- 7Department of Pathology, University Hospital Essen, Essen, Germany
- For correspondence or reprints, contact Wolfgang P. Fendler (wolfgang.fendler{at}uk-essen.de).
Statistics from Altmetric.com
Cited By...
Article usage
In this issue
Jump to section
Related Articles
Cited By...
- Are FAP Theranostics Really Happening? Will Radiochemistry or Biology Win?
- Acquisition Duration Optimization Using Visual Grading Regression in [68Ga]FAPI-46 PET Imaging of Oncologic Patients
- Fibroblast Activation Protein-Directed Imaging Outperforms 18F-FDG PET/CT in Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial
- The Role of Fibroblast Activation Protein in Glioblastoma and Gliosarcoma: A Comparison of Tissue, 68Ga-FAPI-46 PET Data, and Survival Data
- Prognostic Implications of 68Ga-FAPI-46 PET/CT-Derived Parameters on Overall Survival in Various Types of Solid Tumors
- 68Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy
- Diagnostic Accuracy of 68Ga-FAPI Versus 18F-FDG PET in Patients with Various Malignancies
- Fibroblast Activation Protein {alpha}-Directed Imaging and Therapy of Solitary Fibrous Tumor
- Tumor-Targeted Interleukin 2 Boosts the Anticancer Activity of FAP-Directed Radioligand Therapeutics
- 68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-FAPI PET Observational Trial
- Evaluation of the Diagnostic Accuracy of FAPI PET/CT in Oncologic Studies: Systematic Review and Metaanalysis
- Evaluation of the Diagnostic Accuracy of FAPI PET/CT in Oncologic Studies: Systematic Review and Metaanalysis
- 18F-FDG PET/CT in the Management of Osteosarcoma
- 68Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective Study
- 18F-FDG PET/CT in the Management of Osteosarcoma
- Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities
- Correlation of 68Ga-FAPi-46 PET Biodistribution with FAP Expression by Immunohistochemistry in Patients with Solid Cancers: Interim Analysis of a Prospective Translational Exploratory Study
- Pitfalls and Common Findings in 68Ga-FAPI PET: A Pictorial Analysis